Abstract
Objective: To evaluate the correlation between triple-negative breast cancer (TNBC) and drug-resistant protein expression, and to provide reference for improving the treatment of TNBC.
Methods: The relevant literature was searched through PubMed, Web of Science, CNKI, WanFang data, along with VIP databases from 2010 to 2024. Literature screening together with data extraction were implemented by two researchers, and literature quality was evaluated. Meta-analysis was implemented on the extracted data by means of RevMan 5.3 software.
Results: There were 7 literatures included, all of which were in English. Meta-analysis results revealed that, compared to non-TNBC, the expression rate of GST-π protein in TNBC was elevated [OR=3.41, 95% CI (2.21, 5.25), P<0.00001], the expression rate of Pgp protein in TNBC was elevated [OR=1.87, 95% CI (1.17, 2.98), P=0.008], the expression rate of P53 protein in TNBC was elevated [OR=3.65, 95% CI (2.25, 5.91), P<0.00001], the expression rate of Ki-67 in TNBC was elevated [OR=1.19, 95% CI (0.54, 1.84), P=0.0004], the expression rate of Topo grade Ⅰ in TNBC was no significance [OR=0.71, 95% CI (0.14, 3.51), P=0.67], the expression rate of Topo grade Ⅱ in TNBC was was no significance [OR=0.56, 95% CI (0.26, 1.21), P=0.14], the expression rate of Topo grade Ⅲ in TNBC was no significance [OR=1.13, 95% CI (0.15, 8.64), P=0.91], the DFS level in TNBC was elevated [OR=0.30, 95% CI (0.15, 0.59), P=0.0005], and the level of OS in TNBC was elevated [OR=0.17, 95% CI (0.11, 0.28), P<0.00001].
Conclusion: There are many drug-resistant proteins in triple-negative breast cancer, which can be more resistant to chemotherapy drugs, so it is necessary to detect drug-resistant proteins during chemotherapy treatment to obtain better clinical treatment effect.
Keywords
References
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.